Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain

References

• Ballantyne JC. Opioid analgesia: perspectives on right use and utility. Pain Physician 2007;10 (3):479-91
   PubMedGoogle Scholar
• Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001;182 (5A Suppl.):11S-8S
   PubMed Web of Science ®Google Scholar
• Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 2003;63 (7):649-71
   PubMed Web of Science ®Google Scholar
• Bell T, Milanova T, Grove G, et al. OBD symptoms impair quality of life and daily activities, regardless of frequency and duration of opioid treatment: results of a US patient survey (PROBE survey). J Pain 2007;8 (4 Suppl. 1):S71(abstract 882)
   Google Scholar
• Cook S, Bell T, Sweeney C, et al. Impact on quality of life of constipation-associated GI symptoms related to opioid treatment in chronic pain patients: PAC-QOL results from the opioid survey. J Pain 2007;8 (4 Suppl. 1):S71(abstract 883)
   Google Scholar
• Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage 2002;23 (1):48-53
   PubMed Web of Science ®Google Scholar
• Cherny N, Ripamonti C, Pereira J, et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 2001;19 (9):2542-54
   PubMed Web of Science ®Google Scholar
• Coluzzi F, Mattia C. Oxycodone. Pharmacological profile and clinical data in chronic pain management. Minerva Anestesiol 2005;71 (7-8):451-60
   PubMedGoogle Scholar
• Kalso E. Oxycodone. Journal of pain and symptom management 2005;29 (5 Suppl.):S47-56
   PubMed Web of Science ®Google Scholar
• Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology 2003;60) 6):927-34
   PubMed Web of Science ®Google Scholar
• Mucci-LoRusso P, Berman BS, Silberstein PT, et al. Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study. Eur J Pain 1998;2) 3):239-49
   PubMed Web of Science ®Google Scholar
• Watson CP, Moulin D, Watt-Watson J, et al. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 2003;105 (1–2):71-8
   PubMed Web of Science ®Google Scholar
• Choi YS, Billings JA. Opioid antagonists: a review of their role in palliative care, focusing on use in opioid-related constipation. J Pain Symptom Manag 2002;24) 1):71-90
   PubMed Web of Science ®Google Scholar
• Handal KA, Schauben JL, Salamone FR. Naloxone. Ann Emerg Med 1983;12 (7):438-45
   PubMed Web of Science ®Google Scholar
• De Schepper HU, Cremonini F, Park MI, et al. Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol Motil 2004;16 (4):383-94
   PubMed Web of Science ®Google Scholar
• Holzer P. Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neuroscience letters 2004;361 (1-3):192-5
   PubMed Web of Science ®Google Scholar
• Sykes NP. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med 1996;10 (2):135-44
   PubMed Web of Science ®Google Scholar
• Meissner W, Leyendecker P, Mueller-Lissner S, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 2008 :doi: 10.1016/j.ejpain.2008.06.012
   PubMed Web of Science ®Google Scholar
• Ventafridda V, Saita L, Ripamonti C, et al. WHO guidelines for the use of analgesics in cancer pain. Int J Tissue React 1985;7 (1):93-6
   PubMedGoogle Scholar
• Frank L, Kleinman L, Farup C, et al. Psychometric validation of a constipation symptom assessment questionnaire. Scand J Gastroenterol 1999;34 (9):870-7
   PubMed Web of Science ®Google Scholar
• Drossman DA, Corazziari E, Talley NJ, et al. ROME II. The Functional Gastrointestinal Disorders. Diagnosis, Pathophysiology and Treatment: A Multinational Consensus. 2nd edn. McLean, VA: Degnon Associates, 2000
   Google Scholar
• Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singap 1994;23 (2):129-38
   PubMedGoogle Scholar
• Committee for Proprietary Medicinal Products (CPMP). Note for Guidance on Clinical Investigation of Medicinal Products for Treatment of Nociceptive Pain. London: EMEA, 2000
   Google Scholar
• Rome Foundation. Guidelines – Rome III Diagnostic Criteria for Functional Gastrointestinal Disorders. J Gastrointestin Liver Dis 2006;15 (3):307-12
   PubMedGoogle Scholar
• Vondrackova D, Leyendecker P, Meissner W, et al. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain 2008: doi:10.1016/j.jpain.2008.06.014
   PubMed Web of Science ®Google Scholar
• Meissner W, Schmidt U, Hartmann M, et al. Oral naloxone reverses opioid-associated constipation. Pain 2000;84 (1):105-9
   PubMed Web of Science ®Google Scholar
• Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008;358 (22):2332-43
   PubMed Web of Science ®Google Scholar
• Yuan CS, Foss JF, O’Connor M, et al. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA 2000;283 (3):367-72
   PubMed Web of Science ®Google Scholar
• Yuan CS, Foss JF, O’Connor M, et al. Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral–cecal transit time. Clin Pharmacol Ther 2000;67 (4):398-404
   PubMed Web of Science ®Google Scholar